Grants paid by Cancer Prevention Initiative Inc
EIN 47-3425850 · Dallas, TX · Form 990, Schedule I · NTEE H30
Cancer Prevention Initiative Inc of Dallas, TX (EIN 47-3425850) reported 13 grants paid totaling $2,605,000 to 8 recipients in tax years 2020–2025, on Form 990, Schedule I. Derived from IRS e-file data, dataset version 2026.09.0, built 2026-09-03.
Grants paid
$2,605,000
13 grants
Recipients
8
distinct organizations
Tax years
2020–2025
5 filings in the corpus
By tax year
| Tax year | Grants paid | Amount paid | Approved for future |
|---|---|---|---|
| 2020 | 4 | $550,000 | — |
| 2021 | 3 | $480,000 | — |
| 2023 | 1 | $200,000 | — |
| 2024 | 2 | $650,000 | — |
| 2025 | 3 | $725,000 | — |
Top recipients
The 8 recipients receiving the most from Cancer Prevention Initiative Inc, by grants paid, out of 8 distinct recipients.
| Recipient | Match | Location | Grants | Total paid | Latest year |
|---|---|---|---|---|---|
| University of Texas Southwestern Medical Center 75-2556007 | A | Dallas, TX | 5 | $855,000 | 2025 |
| University of Texas Md Anderson Cancer Center 74-6001118 | A | Houston, TX | 1 | $450,000 | 2025 |
| Dana Farber Cancer Institute 04-2263040 | A | Boston, MA | 1 | $450,000 | 2024 |
| Memorial Sloan Kettering Cancer Center 13-1924236 | A | New York, NY | 2 | $300,000 | 2025 |
| Beth Israel Deaconess Medical Center 04-2103881 | A | Boston, MA | 1 | $200,000 | 2020 |
| Cleveland Clinic Foundation 34-0714585 | A | Cleveland, OH | 1 | $150,000 | 2021 |
| City of Hope | U | Duarte, CA | 1 | $150,000 | 2020 |
| Southwestern Medical Foundation 75-0945939 | A | Dallas, TX | 1 | $50,000 | 2020 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Every grant
All 13 grant rows this organization reported, most recent first.
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2025 | University of Texas Md Anderson Cancer Center Houston, TX | A | $450,000 | paid | The purpose of the Grant is for the Principal Investigator to carry out the research to develop immune interventions that could reduce the risk of Lynch Syndrome (LS)-related cancers. The goals of the project are to develop vaccines and test their potential to prevent colorectal cancer in a preclinical model of LS and to explore the colonic immune microenvironment. | 202601329349305575 |
| 2025 | Memorial Sloan Kettering Cancer Center New York, NY | A | $150,000 | paid | This project to identify factors that influence the Loss of Heterozygosity (LOH) was initially funded in 2019. Based on the significant progress made in the project, the project was granted additional funding to continue to phase 2 in 2021 and phase 3 in 2024-2025. During phase 3, they will study allele loss under BRCA wildtype and heterozygous conditions. These studies will provide a comparative mechanistic understanding of LOH at BRCA under normal and carrier conditions. This mechanistic understanding will facilitate development of strategies to prevent LOH and thereby prevent cancer development in high-risk individuals. | 202601329349305575 |
| 2025 | University of Texas Southwestern Medical Center Dallas, TX | A | $125,000 | paid | Scientific and administrative oversight of all Cancer Prevention Initiative programs. | 202601329349305575 |
| 2024 | Dana Farber Cancer Institute Boston, MA | A | $450,000 | paid | The objective of this project is to identify aberrantly expressed age-related drivers of cancer in individuals with inherited cancer syndromes related to BRCA mutations. This project will help develop preventive measures such as vaccines targeting cancer-initiating progenitor cells. | 202541329349304734 |
| 2024 | University of Texas Southwestern Medical Center Dallas, TX | A | $200,000 | paid | Scientific and administrative oversight of all Cancer Prevention Initiative programs. | 202541329349304734 |
| 2023 | University of Texas Southwestern Medical Center Dallas, TX | A | $200,000 | paid | Scientific and administrative oversight of all Cancer Prevention Initiative programs. | 202411349349303976 |
| 2021 | University of Texas Southwestern Medical Center Dallas, TX | A | $180,000 | paid | Scientific and administrative oversight of all Cancer Prevention Initiative programs. | 202221309349300807 |
| 2021 | Memorial Sloan Kettering Cancer Center New York, NY | A | $150,000 | paid | The objective of this project is to generate a robust cellular assay that would allow for the screening of hundreds of compounds to identify determinants of Loss of Heterozygosity (LoH) of BRCA genes. LoH is a major driver in cancer initiation. | 202221309349300807 |
| 2021 | Cleveland Clinic Foundation Cleveland, OH | A | $150,000 | paid | The objective of this project is to identify proteins uniquely and highly expressed in breast cancer of BRCA1 mutation carriers. Identification of these proteins can be key to developing preventative vaccines. | 202221309349300807 |
| 2020 | Beth Israel Deaconess Medical Center Boston, MA | A | $200,000 | paid | The objective of this project is to identify cancer risk predictors in the mammary epithelium of BRCA mutation carriers using state-of-the-art single cell analysis techniques. | 202122359349301317 |
| 2020 | City of Hope Duarte, CA | U | $150,000 | paid | The objective of this project is to develop a novel approach to prevention of breast cancer that combines chemoprevention and immunoprevention of breast cancer by repurposing the FDA approved anti-parasitic drug Ivermectin. | 202122359349301317 |
| 2020 | University of Texas Southwestern Medical Center Dallas, TX | A | $150,000 | paid | Scientific and administrative oversight of all Cancer Prevention Initiative programs. | 202122359349301317 |
| 2020 | Southwestern Medical Foundation Dallas, TX | A | $50,000 | paid | Grant to Southwestern Medical Foundation (SWMF) for collaborative project to pursue cancer prevention research in furtherance of the Organization's mission. | 202122359349301317 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Source filings
Every figure above is traceable to one of these IRS e-file returns by its OBJECT_ID.
| Form | Tax year | Period end | Filed | Schema | IRS OBJECT_ID |
|---|---|---|---|---|---|
| 990 | 2025 | 2025-12-31 | not stated | 2025v4.0 | 202601329349305575 |
| 990 | 2024 | 2024-12-31 | not stated | 2024v5.0 | 202541329349304734 |
| 990 | 2023 | 2023-12-31 | not stated | 2023v5.0 | 202411349349303976 |
| 990 | 2021 | 2021-12-31 | not stated | 2021v4.0 | 202221309349300807 |
| 990 | 2020 | 2020-12-31 | not stated | 2020v4.0 | 202122359349301317 |
Derived from IRS Form 990 e-file XML; recipient identities from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The same rows as Parquet: manifest; as JSON: /api/funders/473425850.json.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.